15 January 2021
Innovation Pharmaceuticals announced that the US Food and Drug Administration (FDA) has granted the company fast track designation to investigate Brilacidin, a first-in-class Host Defence Protein mimetic with antiviral, antibacterial, and anti-inflammatory properties for the treatment of Covid-19.
The FDA Philippines has granted its first emergency use authorisation (EUA) to Pfizer and BioNTech’s Covid-19 vaccine, BNT162b2. An EUA is granted to a particular vaccine being developed in a situation when there is no adequate, available, and approved substitute for a preventative vaccine.
Relay Medical and Glow LifeTech announced successful results from their Phase II double-blind, placebo-controlled clinical trial for ArtemiC, a Covid-19 treatment that is based on the latter’s MyCell Technology. The treatment met its primary and secondary endpoints during the trial.